Chinese Journal of Blood Purification ›› 2023, Vol. 22 ›› Issue (1): 52-55.doi: 10.3969/j.issn.1671-4091.2023.01.012

Previous Articles     Next Articles

Investigation on calprotectin as a new target for the diagnosis and treatment of peritoneal dialyis-related peritoneal fibrosis

RUAN Yi-lin, XU Tian, REN Hong   

  1. Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Received:2022-06-13 Revised:2022-08-21 Online:2023-01-12 Published:2023-01-12
  • Contact: 200025 上海,1上海交通大学医学院附属瑞金医院肾内科 E-mail:renhong66@126.com

Abstract: Calprotectin (S100A8/A9) is a Ca2+ binding protein in the S100 protein family, having a wide range of biological activities and serving as a biomarker for many diseases. Peritoneal dialysis-related peritoneal fibrosis is one of the common complications in peritoneal dialysis (PD) patients. Many studies have recently proved that S100A8/A9 plays an important part in the development of peritoneal fibrosis. Our previous study also confirms that S100A8/A9 is up-regulated in peritoneal fibrosis and down-regulated after inhibition of peritoneal fibrosis. This article discusses the prospect of S100A8/A9 as a new target for the diagnosis and treatment of peritoneal fibrosis.

Key words: S100A8/A9, Peritoneal fibrosis, Peritoneal dialysis

CLC Number: